An Open-label, Phase II Study of KPS-0373 in Patients With SCD
An Open-label, Phase II Study of KPS-0373 in Patients With SCD
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
Inclusion Criteria:
Exclusion Criteria:
Hokkaido Region, Japan
Kansai Region, Japan
Kanto Region, Japan